Camila Belen Olivera

Ms. Camila Belen Olivera


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
COCamila Belen Olivera
Camila Belen Olivera
OBOriana Boscolo
Oriana Boscolo
Cecilia Beatriz DobreckyCecilia Beatriz Dobrecky
Cecilia Beatriz Dobrecky
COClaudia Alicia Ortega
Claudia Alicia Ortega
LFLaura Favier
Laura Favier
Silvia Edith LucangioliSilvia Edith Lucangioli
Silvia Edith Lucangioli
Background: Trihexyphenidyl (THP) has been widely used for over three decades as pediatric pharmacotherapy in patients affected by segmental and generalized dystonia. In order to achieve effective and safe pharmacotherapy for this population, new formulations are needed. Objective: The aim of this work is the development of trihexyphenidyl orodispersible minitablets (ODMTs) for pediatric use. Methods: Six different excipients were tested as diluents. The properties of powder mixtures were evaluated before direct compression and pharmacotechnical tests were performed on the final formulation. The determination of the API content, uniformity of dosage, and physicochemical stability studies were analyzed by an HPLC-UV method. Results: The developed ODMTs met pharmacopeia specifications for content, hardness, friability, disintegration, and dissolution tests. The physicochemical stability study performed over 18 months shows that API content remains within 90.0–110.0% at least for this period. Conclusions: These ODMTs will allow efficient, safe, and high-quality pharmacotherapy.